Chemoproteomic mapping of the ligandable ribonucleoproteome using phloroglucinol meroterpenoids
Chemoproteomic mapping of the ligandable ribonucleoproteome using phloroglucinol meroterpenoids
批准号:
10434114
负责人:
Mikail E Abbasov
金额:
$38.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-04-30
关键词:
AddressAutoimmunityBiochemistryCell physiologyCellsChemicalsCodeComplementComplexDefectDevelopmentDrug TargetingEpitopesGene ExpressionGoalsHumanImageImmune responseImmunofluorescence ImmunologicLysineMalignant NeoplasmsMapsMethodsModificationMolecularMolecular BiologyNational Institute of General Medical SciencesNatural ProductsNerve DegenerationPhloroglucinolPhysiologyPropertyProteomicsRNARNA BindingRNA-Binding ProteinsRNA-Protein InteractionResearchRibonucleoproteinsRoleSiteSpecificityTechnologyTherapeuticTherapeutic AgentsTherapeutic EffectTranscriptUntranslated RNAchemoproteomicsdrug discoveryhuman diseaseinnovationprogramsprotein functionsuccesstherapeutic candidatetool
中文摘要
PI研究项目的长期目标是了解rna是如何通过基因调控发挥作用的
英文摘要
The long-term goal of the PI’s research program is to understand how RNAs exert their regulatory effects through
interaction with RNA-binding proteins (RBPs) and identify the basis for their therapeutic effects in human diseases.
RBPs interact with RNAs to form ribonucleoprotein complexes that that control the fate of nearly every transcript.
These roles are essential for normal human physiology, as defects in RBP function are implicated in autoimmunity,
neurodegeneration, cancer, and innate antiviral immune response.
The molecular mechanisms of RNA-protein
interactions (RPIs) that underpin gene expression and form the basis of numerous human diseases remain
obscure. Consequently, RBPs are rapidly emerging as promising targets for the development of chemical probes
and candidate therapeutic agents. The discovery of therapeutically tractable RPIs, however, remains a formidable
challenge. This proposal describes an interdisciplinary program leveraging quantitative chemoproteomics, natural
product synthesis, molecular biology, and biochemistry to exploit reactivity of proteinaceous lysines at the RPI
interface that modulate the structural properties of ribonucleoprotein complexes. Preliminary findings from the PI
demonstrate that phloroglucinol meroterpenoid natural products modulate RPIs through reversible-covalent
modification of RNA-binding lysines in RBPs. The central hypothesis of this proposal is that high occurrence of
reactive lysines at the RPI interface may provide an unprecedented opportunity in the development of precision
chemical tools with specificity for RBPs and on-target potency gained through reversible-covalent modification.
The proposed research program embodies three integrated projects that address specific challenges in
targeting RBPs in human cells. First, the lack of traditional enzymatic pockets or functional epitopes renders RBPs
as canonically intractable targets. This proposal aims to overcome this challenge through reversible-covalent
modification of RNA-binding lysines at the RPI interface using phloroglucinol meroterpenoids. Second, the full
complement of lysines with heightened reactivity at the RPI interface remains unexplored. This proposal aims to
overcome this limitation by using innovative chemoproteomic methods to globally map lysine reactivity and
ligandability directly in human cells. Last, the functional consequences of meroterpenoid-lysine interactions remain
obscure. By leveraging integrative RNA pulldown and extraction methods with RNA-interactome capture and
immunofluorescence imaging, the proposal aims to identify advanced tool compounds that perturb RPIs through
site-selective modification of lysines in RBPs. Overall, the proposed research program is significant because over
the next five years it will deliver innovative chemical tools and proteomic methods that enrich understanding of the
pathophysiological functions of RPIs and identify the basis for their therapeutic effects in human diseases.
This proposal offers progress in a number of NIGMS major research programs, including fundamentals of
molecular properties and interactions (BBCB), coding and noncoding RNA mechanisms of action and function
(GMCDB), and new methods and targets for drug discovery (PPBC).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chemoproteomic mapping of the ligandable ribonucleoproteome using phloroglucinol meroterpenoids
-
批准号:10276752
-
项目类别:
-
资助金额:$38.64万
-
财政年份:2021
-
负责人:Mikail E Abbasov
-
依托单位:
Chemoproteomic mapping of the ligandable ribonucleoproteome using phloroglucinol meroterpenoids
-
批准号:10605354
-
项目类别:
-
资助金额:$38.56万
-
财政年份:2021
-
负责人:Mikail E Abbasov
-
依托单位:
海外基金